N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Sponsor: ORIC Pharmaceuticals • ClinicalTrials.gov ID: NCT07723248

Registry updated: 2026-10-05
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamide) or docetaxel for treating patients with metastatic castration resistant prostate cancer (mCRPC) who were previously treated with abiraterone acetate. The primary objective of this study is to demonstrate superiority in radiographic progression free survival (rPFS) of the investigational arm of rinzimetostat + darolutamide combination versus physician's choice of control: ARPI (darolutamide or enzalutamide) or docetaxel.

Interventions

  • Rinzimetostat (Drug)
    400 mg once daily (QD)
  • Darolutamide (Drug)
    600 mg twice daily (BID)
  • Enzalutamide (Drug)
    160 mg once daily (QD)
  • Docetaxel (Drug)
    75 mg/m2 intravenously (IV) every 21 days for up to 10 cycles

Eligibility criteria

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features * Progressive disease in the setting of surgical or medical castration with evidence of disease progression on treatment with abiraterone acetate in the mCSPC setting or first line mCRPC setting is required * Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate organ function Exclusion Criteria: * Prior treatment for prostate cancer at any stage with cytotoxic chemotherapy, radioligand therapy (ie, 177Lu -PSMA-617, radium-223), ARPIs including apalutamide, darolutamide, and enzalutamide, PARP monotherapy or other systemic anticancer treatment (approved drugs or experimental compounds such as, antibody therapy, immunotherapy, gene or cell therapy, angiogenesis inhibitors, CDK4/6 inhibitors, PRC2 inhibitors) with the following exceptions: 1. Treatment with first-generation antiandrogen agents (eg, bicalutamide, flutamide, nilutamide), but must be discontinued prior to the first dose of study medication 2. Docetaxel treatment is allowed for mCSPC, as long as no signs of failure or disease progression occurred during treatment or within 3 months of treatment completion * Any other anticancer therapy (drug or vaccine which does not meet exclusion criterion 1 above) within 28 days or 5 half-lives (whichever is longer) prior to randomization * Known or suspected brain metastasis or active leptomeningeal disease * Clinically significant cardiovascular disease defined as: * Any medical (including active or clinically significant bacterial, fungal, or viral infection) or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the patient inappropriate for the study * Active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery are excluded

Conditions

Metastatic Castration Resistant Prostate Cancer

Locations

  • SSAK Partners, LLC — Coral Springs, Florida, United States
  • First Urology PSC — Jeffersonville, Indiana, United States
  • Cancer And Hematology Centers Of Western Michigan — Holland, Michigan, United States
  • Urology Specialists of the Carolinas - University Place — Charlotte, North Carolina, United States
  • Gabrail Cancer Center Research — Canton, Ohio, United States
  • Carolina Urologic Research Center — Myrtle Beach, South Carolina, United States
  • Urology Associates — Nashville, Tennessee, United States
  • Urology Clinics Of North Texas — Dallas, Texas, United States
  • Urology Partners of North Texas (UPNT) — Fort Worth, Texas, United States
  • Houston Metro Urology (HMU) — Houston, Texas, United States
  • Summit Urology — Murray, Utah, United States
  • BRCR Global (Network) — San Juan, Puerto Rico
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record